JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Zai Lab Ltd ADR

Geschlossen

BrancheGesundheitswesen

39.43 3.85

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

39.09

Max

39.54

Schlüsselkennzahlen

By Trading Economics

Einkommen

33M

-48M

Verkäufe

-2.6M

106M

Gewinnspanne

-45.487

Angestellte

1,869

EBITDA

19M

-56M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+49.01% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

816M

4.2B

Vorheriger Eröffnungskurs

35.58

Vorheriger Schlusskurs

39.43

Nachrichtenstimmung

By Acuity

50%

50%

176 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Zai Lab Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Aug. 2025, 23:11 UTC

Ergebnisse

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5. Aug. 2025, 22:45 UTC

Ergebnisse

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5. Aug. 2025, 22:39 UTC

Ergebnisse

Great-West Lifeco Logs Lower 2Q Profit

5. Aug. 2025, 21:32 UTC

Ergebnisse

Coupang Posts Higher 2Q Sales Due to Customer Growth

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5. Aug. 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5. Aug. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5. Aug. 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5. Aug. 2025, 23:03 UTC

Market Talk
Ergebnisse

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5. Aug. 2025, 22:22 UTC

Ergebnisse

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5. Aug. 2025, 22:21 UTC

Ergebnisse

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5. Aug. 2025, 22:20 UTC

Ergebnisse

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5. Aug. 2025, 22:18 UTC

Ergebnisse

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5. Aug. 2025, 22:17 UTC

Ergebnisse

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5. Aug. 2025, 22:17 UTC

Ergebnisse

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5. Aug. 2025, 22:16 UTC

Ergebnisse

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5. Aug. 2025, 22:16 UTC

Ergebnisse

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5. Aug. 2025, 22:15 UTC

Ergebnisse

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5. Aug. 2025, 22:13 UTC

Ergebnisse

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5. Aug. 2025, 22:13 UTC

Ergebnisse

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5. Aug. 2025, 22:12 UTC

Ergebnisse

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5. Aug. 2025, 22:12 UTC

Ergebnisse

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5. Aug. 2025, 21:58 UTC

Ergebnisse

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5. Aug. 2025, 21:30 UTC

Ergebnisse

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5. Aug. 2025, 21:26 UTC

Ergebnisse

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5. Aug. 2025, 21:23 UTC

Ergebnisse

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5. Aug. 2025, 21:17 UTC

Ergebnisse

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer-Vergleich

Kursveränderung

Zai Lab Ltd ADR Prognose

Kursziel

By TipRanks

49.01% Vorteil

12-Monats-Prognose

Durchschnitt 56.7 USD  49.01%

Hoch 75 USD

Tief 38.2 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zai Lab Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

6

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

28.13 / 31.12Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

176 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.